Publications Archivi

Nouscom new Science Translational Medicine publication highlighted on Cancer Discovery #ResearchWatch

Nouscom new Science Translational Medicine publication is highlighted on Cancer Discovery #ResearchWatch, describing a novel mechanism of action driven by viral vector-based vaccine platform [...]

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

Nouscom recently published in the Journal for ImmunoTherapy of Cancer a manuscript entitled: “Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, [...]

Nouscom highlights innovative science behind VENUS, its novel algorithm for identifying and prioritizing patient-specific tumor neoantigens for personalized cancer immunotherapy

VENUS (Vaccine-Encoded Neoantigens Unrestricted Selection) is Nouscom’s proprietary algorithm designed to enhance the predictive accuracy of personalized neoantigen selections that may induce an [...]

Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment

Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an [...]

New viral vectors for infectious diseases and cancer

ABSTRACT – Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and finally eradicate smallpox, the concept of using a virus to fight another virus has evolved [...]

Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability

Article entitled ‘A genetic vaccine encoding shared cancer neoantigens to treat tumors with Microsatellite Instability’ published in Cancer Research BASEL, Switzerland – 22. July 2020: Nouscom, [...]

Nouscom demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in combination with Immune Checkpoint Blockade to Eradicate Large Tumors

Article published in Nature Communications BASEL, Switzerland – 19 June 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced [...]

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome

ABSTRACT IMPORTANCE Colorectal carcinomas in patients with Lynch syndrome (LS) arise in a background of mismatch repair (MMR) deficiency, display a unique immune profile with upregulation of [...]